Kevin C Flanagan
Overview
Explore the profile of Kevin C Flanagan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
546
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hiken J, Earls J, Flanagan K, Wellinghoff R, Ponder M, Messina D, et al.
BMC Cancer
. 2025 Jan;
25(1):21.
PMID: 39773366
Background: While immune checkpoint inhibitor (ICI) therapies can significantly improve outcomes for patients with recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC), only about 15-20% benefit from such treatments. Clinical...
2.
Flanagan K, Earls J, Hiken J, Wellinghoff R, Ponder M, McLeod H, et al.
J Immunother Cancer
. 2024 Nov;
12(11).
PMID: 39489541
Background: Despite advances in cancer care and detection, >65% of patients with squamous cell cancer of the head and neck (HNSCC) will develop recurrent and/or metastatic disease. The prognosis for...
3.
Flanagan K, Earls J, Schillebeeckx I, Hiken J, Wellinghoff R, LaFranzo N, et al.
J Cancer Res Clin Oncol
. 2023 Aug;
149(15):14125-14136.
PMID: 37552307
Purpose: Anti-PD-1 therapy provides clinical benefit in 40-50% of patients with relapsed and/or metastatic head and neck squamous cell carcinoma (RM-HNSCC). Selection of anti- PD-1 therapy is typically based on...
4.
Goff P, Riolobos L, LaFleur B, Spraker M, Seo Y, Smythe K, et al.
Clin Cancer Res
. 2022 Feb;
28(8):1701-1711.
PMID: 35115306
Purpose: To characterize changes in the soft-tissue sarcoma (STS) tumor immune microenvironment induced by standard neoadjuvant therapy with the goal of informing neoadjuvant immunotherapy trial design. Experimental Design: Paired pre-...
5.
Schillebeeckx I, Earls J, Flanagan K, Hiken J, Bode A, Armstrong J, et al.
Sci Rep
. 2022 Jan;
12(1):1342.
PMID: 35079117
Anti-PD-1 therapy can provide long, durable benefit to a fraction of patients. The on-label PD-L1 test, however, does not accurately predict response. To build a better biomarker, we created a...
6.
Schroeder B, LaFranzo N, LaFleur B, Gittelman R, Vignali M, Zhang S, et al.
J Immunother Cancer
. 2021 Sep;
9(8).
PMID: 34465597
Background: Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to inhibitors, little...
7.
LaFranzo N, Flanagan K, Quintanilha D
J Vis Exp
. 2020 Mar;
(156).
PMID: 32176206
Immunotherapies show promise in the treatment of oncology patients, but complex heterogeneity of the tumor microenvironment makes predicting treatment response challenging. The ability to resolve the relative populations of immune...
8.
Schillebeeckx I, Armstrong J, Forys J, Hiken J, Earls J, Flanagan K, et al.
J Mol Diagn
. 2020 Feb;
22(4):555-570.
PMID: 32036085
As immuno-oncology drugs grow more popular in the treatment of cancer, better methods are needed to quantify the tumor immune cell component to determine which patients are most likely to...
9.
Murali B, Ren Q, Luo X, Faget D, Wang C, Johnson R, et al.
Cancer Res
. 2018 Aug;
78(19):5618-5630.
PMID: 30093561
The role of the stromal compartment in tumor progression is best illustrated in breast cancer bone metastases, where the stromal compartment supports tumor growth, albeit through poorly defined mechanisms. p38MAPKα...
10.
Flanagan K, Alspach E, Pazolli E, Parajuli S, Ren Q, Arthur L, et al.
Oncotarget
. 2018 Feb;
9(1):21-36.
PMID: 29416593
Tumorigenesis results from the convergence of cell autonomous mutations and corresponding stromal changes that promote tumor cell growth. Senescent cells, which secrete a plethora of pro-tumorigenic factors termed the senescence-associated...